Peptide Library / Detail
Cotadutide
Half-life
Approximately 7 days (extended through depot formulation)
Delivery
Subcutaneous injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
Cotadutide is a dual agonist peptide that simultaneously activates both glucagon-like peptide-1 (GLP-1) and glucagon receptors. It was developed for the treatment of type 2 diabetes, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD). This dual-action peptide combines the glucose-lowering and appetite-suppressing effects of GLP-1 agonism with the metabolic and energy expenditure benefits of glucagon receptor activation.
Usage
Cotadutide is administered via subcutaneous injection, typically on a weekly basis due to its extended half-life formulation. Clinical trials have evaluated various dosing regimens, with research protocols examining doses ranging from lower therapeutic levels to optimized maintenance doses. The peptide utilizes self-assembly technology to create a long-acting depot formulation with controlled release properties.
Mechanism of Action
Cotadutide works through dual receptor agonism: it activates GLP-1 receptors to enhance insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite, while simultaneously activating glucagon receptors to increase energy expenditure, promote lipolysis, and reduce hepatic steatosis. This balanced dual mechanism helps restore insulin sensitivity, preserve pancreatic β-cell function, and dissipate liver fat accumulation. The peptide's pharmacokinetic profile follows therapeutic peptide principles with sustained systemic exposure through controlled-release depot technology.
Benefits(7)
- Significant reduction in HbA1c and improved glycemic control in type 2 diabetes
- Substantial weight loss through combined appetite suppression and increased energy expenditure
- Reduction of hepatic steatosis and improvement in fatty liver disease
- Restoration of insulin sensitivity in metabolic tissues
- Preservation and rescue of pancreatic β-cell function
- Potential benefits for chronic kidney disease in diabetic patients
- Favorable cardiometabolic effects across the metabolic syndrome spectrum
Side Effects(6)
- Gastrointestinal symptoms including nausea and vomiting
- Diarrhea and abdominal discomfort
- Reduced appetite and early satiety
- Potential injection site reactions
- Mild transient increases in heart rate
- Headache and fatigue
Cotadutide — frequently asked questions
What is Cotadutide?
Cotadutide is a dual agonist peptide that simultaneously activates both glucagon-like peptide-1 (GLP-1) and glucagon receptors. It was developed for the treatment of type 2 diabetes, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD). This dual-action peptide combines the glucose-lowering and appetite-suppressing effects of GLP-1 agonism with the metabolic and energy expenditure benefits of glucagon receptor activation.
What is the half-life of Cotadutide?
Cotadutide has an approximate half-life of Approximately 7 days (extended through depot formulation). The half-life determines how often you need to inject to maintain steady blood levels — use the Peptides Calculator half-life calculator to plot your specific dosing schedule and see the decay curve.
How is Cotadutide administered?
Cotadutide is typically delivered via subcutaneous injection. The Peptides Calculator app helps you reconstitute the vial with bacteriostatic water, calculate your exact dose in syringe units, and track each injection.
How does Cotadutide work?
Cotadutide works through dual receptor agonism: it activates GLP-1 receptors to enhance insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite, while simultaneously activating glucagon receptors to increase energy expenditure, promote lipolysis, and reduce hepatic steatosis. This balanced dual mechanism helps restore insulin sensitivity, preserve pancreatic β-cell function, and dissipate liver fat accumulation. The peptide's pharmacokinetic profile follows therapeutic peptide principles with sustained systemic exposure through controlled-release depot technology.
What are the researched benefits of Cotadutide?
Studied benefits of Cotadutide include: Significant reduction in HbA1c and improved glycemic control in type 2 diabetes, Substantial weight loss through combined appetite suppression and increased energy expenditure, Reduction of hepatic steatosis and improvement in fatty liver disease, Restoration of insulin sensitivity in metabolic tissues, Preservation and rescue of pancreatic β-cell function, Potential benefits for chronic kidney disease in diabetic patients, Favorable cardiometabolic effects across the metabolic syndrome spectrum. These are research findings only — Peptides Calculator does not provide medical advice; consult a qualified healthcare professional before starting any peptide protocol.
What are the side effects of Cotadutide?
Reported side effects of Cotadutide include: Gastrointestinal symptoms including nausea and vomiting, Diarrhea and abdominal discomfort, Reduced appetite and early satiety, Potential injection site reactions, Mild transient increases in heart rate, Headache and fatigue. Always discuss potential side effects with a licensed healthcare provider before using any research peptide.
Related peptides
Other weight loss compounds in the Peptides Calculator library.